<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01487915</url>
  </required_header>
  <id_info>
    <org_study_id>UOSG-AMC-1001</org_study_id>
    <secondary_id>KCSG-GU10-16</secondary_id>
    <nct_id>NCT01487915</nct_id>
  </id_info>
  <brief_title>Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma</brief_title>
  <acronym>COACH</acronym>
  <official_title>Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin Un-fit Advanced Urothelial Carcinoma: Randomized Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cisplatin-based chemotherapy is the standard regimen for advanced urothelial carcinoma.

      But cisplatin-unfit patients account for up to 30-40% of patients in clinical practice.

      Recently reported phase II/III trial of EORTC 30986 comparing gemcitabine/carboplatin (GCb)
      with MCAVI (Methotrexate, Carboplatin, Vinblastine) suggested that GCb be the preferred
      regimen over MCAVI based on the response rates, adverse events, and severe acute toxicities.

      But the grade 3 or worse toxicities associated with GCb are not infrequent and need more
      effective and more tolerable regimens.

      GemOx has been reported to be effective and have very favorable toxicity profiles.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Response rate based on RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>12 months</time_frame>
    <description>Safety according to NCI CTCAE v.4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Advanced Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>GCb</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine plus Carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GemOx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine plus Oxaliplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GCb</intervention_name>
    <description>Gemcitabine 1000 mg/㎡ D1, D8 plus Carboplatin AUC=4.5 D1 every 3 weeks</description>
    <arm_group_label>GCb</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GemOx</intervention_name>
    <description>Gemcitabine 1000 mg/㎡ D1 plus Oxaliplatin 100 mg/㎡ D1 every 2 weeks</description>
    <arm_group_label>GemOx</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cytologically of histologically confirmed urothelial carcinoma

          -  Locally advanced or metastatic disease

          -  Measurable disease according to RECIST v.1.1

          -  ECOG PS 0-2

          -  Cisplatin-unfit condition (any of the followings: NYHA functional class 3, creatinine
             clearance 30-60 ml/min, and ECOG PS=2)

          -  Adequate organ function

          -  Chemotherapy-naive

        Exclusion Criteria:

          -  Histology other than urothelial carcinoma, but squamous cell carcinoma or
             adenocarcinoma mixed with urothelial carcinoma are allowed

          -  CNS metastases

          -  Peripheral neuropathy grade 2 or worse

          -  Serious medical or surgical conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jae-Lyun Lee, MD, PhD</last_name>
    <phone>82 2 3010 5977</phone>
    <email>jaelyun@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeong-Mi Ko, MSc</last_name>
    <email>crnonc8@amc.seoul.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Keimyeong University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Seok Song, MD, PhD.</last_name>
    </contact>
    <contact_backup>
      <last_name>Jin Young Kim, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Chungnam University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo Jin Lee, MD, PhD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyeong Hwa Park, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeong-Mi Ko, MSc</last_name>
      <email>crnonc8@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Jae-Lyun Lee, MD, PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jin-Hee Ahn, MD, PhD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hanjong Ahn, MD, PhD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun Hyuk Hong, MD, PhD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cheryn Song, MD, PhD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cheong Soo Kim, MD, PhD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chung Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hee Joon Kim, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2011</study_first_submitted>
  <study_first_submitted_qc>December 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2011</study_first_posted>
  <last_update_submitted>September 22, 2014</last_update_submitted>
  <last_update_submitted_qc>September 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>JLee</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Cisplatin-unfit condition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

